Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.72 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.72 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.72 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.70 |
| ▸ | KDM1A | O60341 | 3/20 | 0.70 |
| ▸ | LSS | P48449 | 1/20 | 0.69 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.66 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.63 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.63 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.61 |
| ▸ | PPARG | P37231 | 1/20 | 0.61 |
| ▸ | PPARA | Q07869 | 1/20 | 0.61 |
| ▸ | MLYCD | O95822 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20477562 | 0.87 | L3MBTL1 (0.69) | HDAC1KDM1ALSSMAPK14EPHX2 | |
| SCHEMBL3455877 | 0.87 | LSS (0.69) | HDAC6HDAC8HDAC3HDAC1KDM1A | |
| SCHEMBL4497840 | 0.87 | LSS (0.69) | HDAC6HDAC8HDAC3HDAC1KDM1A | |
| SCHEMBL507529 | 0.86 | LSS (0.68) | HDAC1KDM1ALSSMAPK14EPHX2 | |
| SCHEMBL20477571 | 0.86 | MEN1 (0.73) | LSSMAPK14EPHX2PPARGPPARA | |
| SCHEMBL3158764 | 0.86 | EPHX2 (0.73) | HDAC1KDM1ALSSMAPK14EPHX2 | |
| SCHEMBL13947580 | 0.86 | LSS (0.72) | HDAC6HDAC8HDAC3LSSMAPK14 | |
| SCHEMBL2634030 | 0.85 | MAPK14 (0.76) | HDAC6HDAC8HDAC3HDAC1LSS | |
| SCHEMBL11979758 | 0.85 | MAPK14 (0.76) | HDAC6HDAC8HDAC1LSSMAPK14 | |
| SCHEMBL8239268 | 0.84 | HDAC1 (0.61) | HDAC6HDAC8HDAC3HDAC1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214862-A1 | Aromatic dicarboxylic acid derivatives | LESER-REIFF ULRIKE | 2004-10-28 | — | — | US | claimed |
| US-20030013757-A1 | Aromatic dicarboxylic acid derivatives | HOFFMANN-LA ROCHE INC. | 2003-01-16 | — | — | US | claimed |
| US-20040214862-A1 | Aromatic dicarboxylic acid derivatives | LESER-REIFF ULRIKE | 2004-10-28 | — | — | US | disclosed |
| US-6784173-B2 | ANTIPROLIFERATIVE AGENTS; ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2004-08-31 | — | — | US | disclosed |
| EP-1401824-A2 | AROMATIC HYDROXAMIC ACID DERIVATIVES USEFUL AS HDAC INHIBITORS | F. Hoffman-la Roche AG (CH) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003011851-A2 | AROMATIC HYDROXAMIC ACID DERIVATIVES USEFUL AS HDAC INHIBITORS | F. HOFFMAN-LA ROCHE AG (CH) | 2003-02-13 | — | — | WO | disclosed |
| US-20030013757-A1 | Aromatic dicarboxylic acid derivatives | HOFFMANN-LA ROCHE INC. | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214862-A1 | Aromatic dicarboxylic acid derivatives | HDAC1, HDAC2, HDAC11 | HDAC6 13/4885HDAC8 6/4885HDAC3 4/4885 |
| US-20030013757-A1 | Aromatic dicarboxylic acid derivatives | HDAC1, HDAC2, HDAC11 | HDAC6 13/4885HDAC8 6/4885HDAC3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.